# Synergistic hyperinflammation in IgA vasculitis complicated by varicella-induced HLH: a case report

**Authors:** Xiaoli He, Yu Zhou, Lina Qiao, Deyuan Li, Zhongqiang Liu, Guoyan Lu

PMC · DOI: 10.3389/fimmu.2025.1675483 · Frontiers in Immunology · 2026-01-12

## TL;DR

A boy with IgA vasculitis developed severe HLH from VZV infection, and a combination treatment led to recovery, highlighting immune system interactions.

## Contribution

This case report highlights the synergistic risk of HLH when VZV infection overlaps with IgA vasculitis, offering insights into treatment and immune monitoring.

## Key findings

- A multimodal therapy combining acyclovir, IVIG, TPE, etoposide, and dexamethasone achieved rapid remission in VZV-HLH.
- Lymphocytopenia may serve as a biomarker for disease severity and recovery in VZV-induced HLH.
- The case suggests immune dysregulation from overlapping VZV and IgA vasculitis increases HLH risk.

## Abstract

Varicella-zoster virus (VZV)-induced hemophagocytic lymphohistiocytosis (HLH) is a rare but fatal complication, particularly in immunocompromised hosts. We present an 11-year-old boy with IgA vasculitis who developed severe VZV-HLH complicated by disseminated intravascular coagulation (DIC), acute liver failure and persistent lymphocytopenia. A multimodal therapeutic approach that combining high-dose acyclovir, intravenous immunoglobulin (IVIG), therapeutic plasma exchange (TPE), reduced-dose etoposide (75 mg/m²), and dexamethasone achieved rapid disease remission. This case demonstrates synergistic risk of HLH when VZV infection overlaps with IgA vasculitis, likely via compounded immune dysregulation. This case suggests that when varicella zoster virus infection overlaps with IgA vasculitis, it may synergistically increase the risk of HLH through aggravated immune dysregulation. In infection-triggered HLH, step-wise immunomodulatory therapy has a key role. What’s more, lymphocytopenia may be used as a biomarker to assess disease severity and recovery, and this finding emphasizes the need for long-term immune monitoring. This case provides valuable insights into the pathogenesis and management of VZV related HLH in rheumatic and immune diseases.

## Linked entities

- **Chemicals:** acyclovir (PubChem CID 135398513), dexamethasone (PubChem CID 5743), etoposide (PubChem CID 36462)
- **Diseases:** IgA vasculitis (MONDO:0019167), hemophagocytic lymphohistiocytosis (MONDO:0015540), disseminated intravascular coagulation (MONDO:0001243), acute liver failure (MONDO:0019542)

## Full-text entities

- **Diseases:** acute liver failure (MESH:D017114), lymphocytopenia (MESH:D008231), rheumatic and immune diseases (MESH:D012216), IgA vasculitis (MESH:D011695), varicella (MESH:D002644), immune dysregulation (OMIM:614878), infection (MESH:D007239), DIC (MESH:D004211), HLH (MESH:D051359), VZV infection (MESH:D000073618)
- **Chemicals:** acyclovir (MESH:D000212), etoposide (MESH:D005047), dexamethasone (MESH:D003907)
- **Species:** Human alphaherpesvirus 3 (Varicella-zoster virus, no rank) [taxon 10335]

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12833449/full.md

## Figures

3 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12833449/full.md

## References

29 references — full list in the complete paper: https://tomesphere.com/paper/PMC12833449/full.md

---
Source: https://tomesphere.com/paper/PMC12833449